Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression

Background: Cutaneous melanoma is a highly malignant tumor which tends to metastasize in the early stage and leads to poor prognosis. Hematogenous and lymphatic metastasis are common in the dissemination of melanoma. Rapamycin, an mTOR inhibitor, was reported to have anti-angiogenic and anti-lymphan...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Xu, Yuan, Wen, Guo-Zhong, Wang, Qian, Yuan, Si-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580124/
https://www.ncbi.nlm.nih.gov/pubmed/31354297
http://dx.doi.org/10.2147/OTT.S205160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580124/
https://www.ncbi.nlm.nih.gov/pubmed/31354297
http://dx.doi.org/10.2147/OTT.S205160

Ejemplares similares